Repeated infusions of thrombin-activated CD40L-deficient platelets reduce leukocyte recruitment, suppress platelet-leukocyte aggregate formation, and inhibit thrombosis, thereby attenuating atherosclerosis progression (49). The gene discussed is CD40LG; the disease is atherosclerosis.